Form 4: ALX Oncology Director Acquires Stock Options

Corey Goodman, a director at ALX Oncology Holdings Inc., was granted stock options for 40,400 shares at an exercise price of $1.65.

Summary

• Corey Goodman, a director at ALX Oncology Holdings Inc., has been granted stock options to purchase 40,400 shares of common stock.
• The exercise price for these options is $1.65 per share.
• The options vest in 12 equal monthly installments starting on February 21, 2025.
• The options expire on January 20, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally positive for aligning interests but not a major market-moving event.

Positives

• The grant of stock options to a director aligns their interests with the company's performance.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotech industry, often used to attract and retain talent.
• Vesting schedules, like the 12-month monthly vesting in this case, are typical to ensure long-term commitment.
• The exercise price of $1.65 is specific to ALX Oncology's stock and market conditions at the time of the grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the director, which can be beneficial for the company's performance.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, ALX Oncology, director, equity, Form 4